{"entity":{"type":"insider","cik":"0001872422","url":"/insider/0001872422","json_url":"/insider/0001872422.json","name":"Sundaram Preethi","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":5,"n_filings":3,"first":"2022-09-16","last":"2025-06-12","span_basis":"filed_date"},"name_variants":[{"name":"Sundaram Preethi","source":"filing","n_filings":3,"first_seen":"2022-09-16","last_seen":"2025-06-12"}],"transactions":[{"id":5182370,"accession":"0001161697-25-000189","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001161697-25-000189","line_url":"/filing/0001161697-25-000189#line-2","is_derivative":false,"issuer_cik":"0001369568","issuer_name":"CATALYST PHARMACEUTICALS, INC.","issuer_ticker":"CPRX","issuer_name_source":null,"issuer_url":"/issuer/0001369568","owner_cik":"0001872422","owner_name":"Sundaram Preethi","owner_display_name":"Sundaram Preethi","owner_url":"/insider/0001872422","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock, par value $0.001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600.0,"shares_display":"1,600","price_per_share":26.42,"price_display":"26.42","price_state":"stated","total_value":42272.0,"total_display":"42,272.00","total_whole":"42,272","shares_owned_after":41081.0,"shares_owned_after_display":"41,081","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-11","filed_date":"2025-06-12","scope":"insider"},{"id":5182364,"accession":"0001161697-25-000189","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001161697-25-000189","line_url":"/filing/0001161697-25-000189#line-1","is_derivative":false,"issuer_cik":"0001369568","issuer_name":"CATALYST PHARMACEUTICALS, INC.","issuer_ticker":"CPRX","issuer_name_source":null,"issuer_url":"/issuer/0001369568","owner_cik":"0001872422","owner_name":"Sundaram Preethi","owner_display_name":"Sundaram Preethi","owner_url":"/insider/0001872422","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock, par value $0.001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2324.0,"shares_display":"2,324","price_per_share":26.41,"price_display":"26.41","price_state":"stated","total_value":61376.84,"total_display":"61,376.84","total_whole":"61,377","shares_owned_after":42681.0,"shares_owned_after_display":"42,681","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-12","scope":"insider"},{"id":6422024,"accession":"0001161697-22-000550","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001161697-22-000550","line_url":"/filing/0001161697-22-000550","is_derivative":false,"issuer_cik":"0001369568","issuer_name":"CATALYST PHARMACEUTICALS, INC.","issuer_ticker":"CPRX","issuer_name_source":null,"issuer_url":"/issuer/0001369568","owner_cik":"0001872422","owner_name":"Sundaram Preethi","owner_display_name":"Sundaram Preethi","owner_url":"/insider/0001872422","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common stock, par value $0.001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":56786.0,"shares_display":"56,786","price_per_share":16.375,"price_display":"16.38","price_state":"stated","total_value":929870.75,"total_display":"929,870.75","total_whole":"929,871","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-11","filed_date":"2022-11-15","scope":"insider","n_lines":2},{"id":6141508,"accession":"0001161697-22-000469","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001161697-22-000469","line_url":"/filing/0001161697-22-000469#line-2","is_derivative":false,"issuer_cik":"0001369568","issuer_name":"CATALYST PHARMACEUTICALS, INC.","issuer_ticker":"CPRX","issuer_name_source":null,"issuer_url":"/issuer/0001369568","owner_cik":"0001872422","owner_name":"Sundaram Preethi","owner_display_name":"Sundaram Preethi","owner_url":"/insider/0001872422","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common stock, par value $0.001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18214.0,"shares_display":"18,214","price_per_share":14.49,"price_display":"14.49","price_state":"stated","total_value":263920.86,"total_display":"263,920.86","total_whole":"263,921","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-15","filed_date":"2022-09-16","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":5,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":5,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":5},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001369568","name":"CATALYST PHARMACEUTICALS, INC.","url":"/issuer/0001369568","role":"Officer (Chief Strategy Officer)","n_filings":3,"first_seen":"2022-09-16","last_seen":"2025-06-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001872422","retrieved_at":"2026-08-23T20:44:58+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}